DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: Singulair

Summary for Tradename: Singulair

Patents:1
Applicants:1
NDAs:3
Suppliers: see list11
drug
patent expirations by year for
 Singulair

Pharmacology for Tradename: Singulair

Clinical Trials for: Singulair

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
Status: Completed Condition: Asthma

The Effect of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity
Status: Completed Condition: Cough; Bronchial Hyperreactivity

Genotype Stratified Pharmacokinetic Study of Montelukast
Status: Recruiting Condition: Asthma

Study of the Safety and Pharmacokinetics of MK-0476 in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)
Status: Completed Condition: Perennial Allergic Rhinitis

The Effect of Montelukast Treatment in Wheezy Infants
Status: Completed Condition: Lung Disease, Obstructive; Signs and Symptoms, Respiratory

Safety and the Pharmacokinetic Study of Characteristics of MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma
Status: Recruiting Condition: Asthma and Allergic Rhinitis

Roflumilast Plus Montelukast in Adults With Severe Asthma
Status: Completed Condition: Asthma

Bioequivalence Study of Montelukast 10 mg Tablets
Status: Completed Condition: Asthma

Bioequivalence Study of Montelukast 5 mg Chewable
Status: Completed Condition: Asthma

Montelukast in Very Low Birthweight Infants
Status: Completed Condition: Bronchopulmonary Dysplasia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
SINGULAIR
montelukast sodium
GRANULE;ORAL021409Jul 26, 2002RXYes<disabled><disabled>
Merck
SINGULAIR
montelukast sodium
GRANULE;ORAL021409Jul 26, 2002RXYes8,007,830<disabled>Y<disabled>
Merck
SINGULAIR
montelukast sodium
TABLET, CHEWABLE;ORAL020830Feb 20, 1998RXYes<disabled><disabled>
Merck
SINGULAIR
montelukast sodium
TABLET, CHEWABLE;ORAL020830Mar 3, 2000RXNo<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SINGULAIR

Drugname Dosage Strength RLD Submissiondate
montelukastTablets10 mgSingulair2/20/2007
montelukast sodiumChewable Tablets4 mg and 5 mgSingulair12/26/2006

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc